Spyre Therapeutics, Inc.
Clinical trials sponsored by Spyre Therapeutics, Inc., explained in plain language.
A biotechnology company developing antibody therapies for inflammatory bowel disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug SPY002-072 aims to tame multiple inflammatory joint diseases Results expected Oct 2026 (estimated) May already have reported ↗
- New drug SPY003-207 tested in humans for first time Results expected Nov 2026 (estimated)
- New antibody cocktail aims to tame ulcerative colitis Results expected Jun 2027 (estimated) May already have reported ↗